Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Long Protocol and Growth Hormone in Poor Responders
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Woman's Health University Hospital, Egypt
- Target Recruit Count
- 240
- Registration Number
- NCT02338206
- Locations
- 🇪🇬
Kasr el aini hospital, Cairo, Egypt
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02311894
- Locations
- 🇺🇸
Barry J Reiner, MD, LLC, Baltimore, Maryland, United States
🇺🇸Endocrine Associates of Dallas, Dallas, Texas, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 301
- Registration Number
- NCT02229851
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 131
- Registration Number
- NCT02217345
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Corporacion Parc Tauli
- Target Recruit Count
- 16
- Registration Number
- NCT02205450
- Locations
- 🇪🇸
Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
Antagonist Protocol in Poor Responders
- Conditions
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 141
- Registration Number
- NCT02195947
- Locations
- 🇪🇬
Kasr Al Aini, Cairo, Egypt
Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF
- Conditions
- Interventions
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Center for Human Reproduction
- Target Recruit Count
- 30
- Registration Number
- NCT02179255
- Locations
- 🇺🇸
Center for Human Reproduction, New York, New York, United States
Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2018-02-05
- Target Recruit Count
- 34
- Registration Number
- NCT02114775
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02092077
- Locations
- 🇧🇾
Teva Investigational Site 68016, Minsk, Belarus
🇧🇬Teva Investigational Site 59060, Varna, Bulgaria
🇬🇪Teva Investigational Site 81022, Tbilisi, Georgia
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT02018172
- Locations
- 🇫🇷
Hôpital des Enfants, CHU de Toulouse, Toulouse, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.